NeuroSense Therapeutics (NRSN) Stock Analysis

What NeuroSense Therapeutics does

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

Key metrics

ETFs linked to NRSN

Broad-market and Healthcare sector ETFs an investor holding NeuroSense Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NRSN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for NeuroSense Therapeutics?

NeuroSense Therapeutics trades under the ticker NRSN on NASDAQ.

Which exchange is NRSN listed on?

NRSN is listed on NASDAQ.

What sector does NeuroSense Therapeutics operate in?

NeuroSense Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NRSN in a portfolio?

PortView shows NRSN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.